CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Gr. Inc. Y/Y Annual
Scynexis Inc   (SCYX)
Other Ticker:  
 
 

SCYX's Gross Income Growth by Quarter and Year

Scynexis Inc 's Gross Income results by quarter and year




SCYX Gross Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 1.52 0.60 0.00
III Quarter September 1.76 1.56 0.52 0.00
II Quarter June 131.45 1.32 0.00 0.00
I Quarter March 1.13 0.69 12.05 0.00
FY   134.34 5.09 13.17 0.00



SCYX Gross Income third quarter 2023 Y/Y Growth Comment
Scynexis Inc reported Gross Income increase of 12.88% year on year in the third quarter 2023, to $ 1.76 millions, this is lower than Scynexis Inc 's recent average Gross Income surge of 641.18%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Gross Income growth. While Scynexis Inc ' s Gross Income growth of 12.88% ranks overall at the positon no. 809 in the third quarter 2023.

Explain Gross Income Margin


SCYX Gross Income ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - 153.33 % - -
III Quarter September 12.88 % 200 % - -
II Quarter June 9858.33 % - - -
I Quarter March 63.77 % -94.27 % - -
FY   - -61.35 % - -

Financial Statements
Scynexis Inc 's third quarter 2023 Gross Income $ 1.76 millions SCYX's Income Statement
Scynexis Inc 's third quarter 2022 Gross Income $ 1.56 millions Quarterly SCYX's Income Statement
New: More SCYX's historic Gross Income Growth >>


SCYX Gross Income (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - -2.56 % 15.38 % -
III Quarter September -98.66 % 18.18 % - -
II Quarter June 11532.74 % 91.3 % - -
I Quarter March -25.66 % 15 % - -
FY (Year on Year)   - -61.35 % - -


Compare SCYX Profitability >> Back to SCYX Growth rate Comparisons >>


Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #162
Overall #809

Gross Income Y/Y Growth Statistics
High Average Low
4244.06 % 641.18 % -92.82 %
(Jun 30 2023)   (Dec. 30, 2015)
Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #162
Overall #809
Gross Income Y/Y Growth Statistics
High Average Low
4244.06 % 641.18 % -92.82 %
(Jun 30 2023)   (Dec. 30, 2015)

Gross Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Scynexis Inc 's Q/Q Gross Income Growth


Gross Income Q/Q Growth Statistics
High Average Low
11533.1 % 431.46 % -100 %
(Jun 30 2023)  


SCYX's III. Quarter Q/Q Gross Income Comment
In the III. Quarter 2023 Scynexis Inc realized fall in Gross Income sequentially by -98.66% to $ 1.76 millions, from $ 131.45 millions released in the previous reporting period.

Even periodic factors which commonly fuel III. Quarter 2023 performance, that plainly was not enough to recover Major Pharmaceutical Preparations's company III. Quarter 2023 performance, Anna Reed, Major Pharmaceutical Preparations industry veteran said.

Within Major Pharmaceutical Preparations industry 242 other companies have achieved higher Gross Income quarter on quarter growth. While Scynexis Inc 's Gross Income growth quarter on quarter, overall rank is 3859.


Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #243
Healthcare Sector #624
Overall #3859
Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #243
Healthcare Sector #624
Overall #3859
Gross Income Q/Q Growth Statistics
High Average Low
11533.1 % 431.46 % -100 %
(Jun 30 2023)  


SCYX's III. Quarter Q/Q Gross Income Comment
In the III. Quarter 2023 Scynexis Inc reported fall in Gross Income from the second quarter by -98.66% to $ 1.76 millions, from $ 131.45 millions declared in the previous reporting period.

Albeit cyclical circumstance which normally elevate III. Quarter 2023 Gross Income, this simply has not been substantial to salvage Major Pharmaceutical Preparations's company III. Quarter 2023 performance, Anna Reed, Major Pharmaceutical Preparations industry veteran wrote and wrote that average quarter on quarter Gross Income growth is at 431.46% for Scynexis Inc .

Within Major Pharmaceutical Preparations industry 242 other companies have achieved higher Gross Income quarter on quarter growth. While Scynexis Inc 's Gross Income growth quarter on quarter, overall rank is 3859.


Scynexis Inc 's 12 Months Gross Income Growth Year on Year


Gross Income TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Gross Income 12 Months Ending $ 135.87 $ 135.67 $ 5.53 $ 5.09 $ 4.16
Y / Y Gross Income Growth (TTM) 3162.94 % 4244.06 % - - -
Year on Year Gross Income Growth Overall Ranking # 10 # 19 # 0 # 0 # 0
Seqeuential Gross Income Change (TTM) 0.15 % 2351.48 % 8.7 % 22.26 % 33.33 %
Seq. Gross Income Growth (TTM) Overall Ranking # 809 # 873 # 849 # 0 # 815

New: More SCYX's historic Gross Income Growth >>



Cumulative Gross Income growth Comment
Assuming the Scynexis Inc 's fiscal year would have ended in Sep 30 2023, Scynexis Inc would have reprted above average annual Gross Income surge of 3162.94% year on year, of $ 136 millions.
This marks a slow-down of the companys growth trends and from the 4244.06% surge in Jun 30 2023.

Looking into Healthcare sector trailing twelve month Gross Income increase, only one company had higher growth. While Total ranking has impoved so far to 10, from total ranking in previous quarter at 19.

Gross Income TTM Q/Q Growth Statistics
High Average Low
4244.06 %
641.18 %
-92.82 %
 

Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 2
Overall # 10

Gross Income TTM Y/Y Growth Statistics
High Average Low
4244.06 %
641.18 %
-92.82 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 162
S&P 500 # 809
Cumulative Gross Income growth Comment
Assuming the Scynexis Inc 's fiscal year would have ended in Sep 30 2023, Scynexis Inc would have reprted above average annual Gross Income surge of 3162.94% year on year, of $ 136 millions.
This marks a slow-down of the companys growth trends and from the 4244.06% surge in Jun 30 2023.

Looking into Healthcare sector trailing twelve month Gross Income increase, only one company had higher growth. While Total ranking has impoved so far to 10, from total ranking in previous quarter at 19.

Gross Income TTM Q/Q Growth Statistics
High Average Low
4244.06 %
641.18 %
-92.82 %
 


Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 77
Healthcare Sector # 2
Overall # 10

Gross Income TTM Y/Y Growth Statistics
High Average Low
4244.06 %
641.18 %
-92.82 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 77
Sector # 162
S&P 500 # 809




Other Gross Income Growth
Major Pharmaceutical Preparations Industry Gross Income Growth Trends and Statistics
Healthcare Sector Gross Income Growth Statistics
Gross Income Growth Trends for overall market
SCYX's Gross Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Income Growth
Lowest Ranking Gross Income Growth
Gross Income Growth for SCYX's Competitors
Gross Income Growth for Scynexis Inc 's Suppliers
Gross Income Growth for SCYX's Customers

You may also want to know
SCYX's Annual Growth Rates SCYX's Profitability Ratios SCYX's Asset Turnover Ratio SCYX's Dividend Growth
SCYX's Roe SCYX's Valuation Ratios SCYX's Financial Strength Ratios SCYX's Dividend Payout Ratio
SCYX's Roa SCYX's Inventory Turnover Ratio SCYX's Growth Rates SCYX's Dividend Comparisons



Companies with similar Gross Income surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Gross Income for the quarter ending Sep 30 2023
Zomedica Corp 22.49%$ 22.494 millions
Veracyte inc 22.42%$ 22.420 millions
Zynex inc 21.83%$ 21.833 millions
Guardant Health Inc 21.83%$ 21.827 millions
Iradimed Corporation21.77%$ 21.765 millions
Integer Holdings Corporation21.72%$ 21.723 millions
Corcept Therapeutics Inc21.48%$ 21.483 millions
Biodesix Inc 21.46%$ 21.464 millions
Vericel Corporation21.30%$ 21.301 millions
Rigel Pharmaceuticals Inc21.24%$ 21.236 millions
Si bone inc 21.15%$ 21.151 millions
Harvard Bioscience Inc20.99%$ 20.991 millions
Lifestance Health Group Inc 20.84%$ 20.838 millions
Mimedx Group Inc 20.58%$ 20.578 millions
Seagen Inc 20.19%$ 20.195 millions
Alpine Immune Sciences Inc 20.03%$ 20.031 millions
Aquestive Therapeutics Inc 19.98%$ 19.977 millions
Amneal Pharmaceuticals Inc 19.72%$ 19.719 millions
Atricure Inc 19.70%$ 19.698 millions
Bolt Biotherapeutics Inc 19.70%$ 19.697 millions
Inspiremd Inc 19.67%$ 19.672 millions
Orthopediatrics Corp19.56%$ 19.560 millions
Airsculpt Technologies Inc 19.22%$ 19.222 millions
Werewolf Therapeutics Inc 18.65%$ 18.652 millions
Ensign Group Inc18.61%$ 18.612 millions
Cano Health Inc 18.50%$ 18.502 millions
Biocryst Pharmaceuticals Inc 18.48%$ 18.481 millions
Privia Health Group Inc 18.44%$ 18.443 millions
Bionexus Gene Lab Corp 18.31%$ 18.308 millions
Livanova Plc18.07%$ 18.070 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com